大脑和眼部神经退行性疾病中的神经保护：过去的经验与未来的方向
Neuroprotection in neurodegenerations of the brain and eye: Lessons from the past and directions for the future.
作者信息
Levin Leonard A, Patrick Christopher, Choudry Nozhat B, Sharif Najam A, Goldberg Jeffrey L
机构信息
Departments of Ophthalmology and Visual Sciences, Neurology & Neurosurgery, McGill University, Montreal, QC, Canada.
TELUS Health, Ottawa, ON, Canada.
出版信息
Front Neurol. 2022 Aug 12;13:964197. doi: 10.3389/fneur.2022.964197. eCollection 2022.
BACKGROUND
Neurological and ophthalmological neurodegenerative diseases in large part share underlying biology and pathophysiology. Despite extensive preclinical research on neuroprotection that in many cases bridges and unifies both fields, only a handful of neuroprotective therapies have succeeded clinically in either.
MAIN BODY
Understanding the commonalities among brain and neuroretinal neurodegenerations can help develop innovative ways to improve translational success in neuroprotection research and emerging therapies. To do this, analysis of why translational research in neuroprotection fails necessitates addressing roadblocks at basic research and clinical trial levels. These include optimizing translational approaches with respect to biomarkers, therapeutic targets, treatments, animal models, and regulatory pathways.
CONCLUSION
The common features of neurological and ophthalmological neurodegenerations are useful for outlining a path forward that should increase the likelihood of translational success in neuroprotective therapies.
背景
神经退行性疾病和眼科神经退行性疾病在很大程度上具有共同的生物学和病理生理学基础。尽管在神经保护方面进行了广泛的临床前研究，在许多情况下将这两个领域联系起来并使其统一，但在这两个领域中临床上成功的神经保护疗法却寥寥无几。
主体
了解脑和神经视网膜神经退行性变之间的共性有助于开发创新方法，以提高神经保护研究和新兴疗法的转化成功率。要做到这一点，分析神经保护转化研究失败的原因需要解决基础研究和临床试验层面的障碍。这些障碍包括在生物标志物、治疗靶点、治疗方法、动物模型和监管途径方面优化转化方法。
结论
神经退行性疾病和眼科神经退行性疾病的共同特征有助于勾勒出一条前进的道路，这应该会增加神经保护疗法转化成功的可能性。
Zotero 插件